Figure 2.

Cytotoxic activity of human primary CD8 T cells engineered to express ACE2 CAR or anti‐Spike CAR. (a) Cytotoxicity assay against Spike‐expressing target cells using ACE2 CAR or anti‐Spike CAR‐expressing CD8 T cells as effector cells. (b) CAR‐engineered T cells cytotoxicity assays with Spike‐expressing 293 target cells at different Effector:Target ratios. CD8 T cells transduced with anti‐CD19 CAR lentiviruses were used as control effector cells. Effector CD8 T cells were identified with CD8 staining, while target cells were gated based on GFP (Spike) expression. Activation of effector cells and CAR expression were determined with CD25 expression after gating on CD8 T cells 2 days after coculture. (c) Cytotoxicity of ACE2 CAR (blue) and anti‐Spike CAR (purple) T cells normalised to anti‐CD19 CAR‐T cells at different Effector:Target ratios and using Spike‐expressing 293 cells as the target. (d) CAR‐engineered T cells cytotoxicity assays with Spike‐expressing target B cell line (T2 cells) at 8:1 E:T ratio. Wild‐type CD8 T cells were used as a negative control and anti‐CD19 CAR‐expressing CD8 T cells were used as a positive control. Panels show representative experiments replicated three times with similar results.